Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
cancer
6
×
life sciences
national blog main
san francisco blog main
6
×
boston top stories
national top stories
san francisco top stories
cancer drugs
clinical trials
europe blog main
ipo
europe top stories
fda
indiana blog main
indiana top stories
novartis
sanofi
venture capital
biogen
blueprint medicines
boulder/denver blog main
boulder/denver top stories
deals
deerfield management
detroit blog main
detroit top stories
eli lilly
gilead sciences
melinta therapeutics
national
new york blog main
new york top stories
non-small cell lung cancer
raleigh-durham blog main
raleigh-durham top stories
revolution medicines
roche
san diego blog main
What
medicines
6
×
ipo
cancer
drug
research
bio
covid
fda
new
proteins
revolution
roundup
targets
acquisitions
activity
address
announced
approval
approvals
approves
biogen
biotech
black
blueprint
cancer’s
carries
ceo
certain
clamped
clinic
collabs
companies
daniel
deal
delays
designed
despite
developing
diamond
disease
Language
unset
6
×
Current search:
medicines
×
cancer
×
" san francisco blog main "
×
unset
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic